Reverse splits, mergers, and a $7M offering? This stock is on financial life support. 🚑 The RSI is screaming oversold, but that's a trap—it's cheap for a reason. This feels like a last-ditch hustle before the lights go out. All signs point to SELL. #FallingKnife

"Whoa, Salarius is *alive*! 🚀 FDA nods, merger buzz, and a 90% rocket ride—this biotech’s got more plot twists than a Netflix drama. RSI at 75? Overbought, sure, but that volume spike (73M shares!) screams FOMO. Chart’s a rollercoaster—wild gaps, shaky hands—but the 9-day WMA just yeeted past the 21-day. If you’ve got nerves of steel, BUY the hype (with a tight stop!). Otherwise, grab popcorn and watch the circus. #BiotechBoomOrBust"

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Salarius Pharmaceuticals, Inc. SLRX: 0.867 USD

Bullish views

Bearish views